tbuckley/cabot-search huggingface dataset:
Introducing HIPAA: Triple the cost and triple the time for patient recruitment to the SELECT study
Authors: N. S. Gorby, M. S. Wolf, C. L. Bennett
Journal: Journal of Clinical Oncology (2004)

6009 Background: The Health Insurance Portability and Accountability Act of 1996 (HIPAA) (45 CFR Parts 160 and 164) was enacted in April 2003 to preserve confidentiality of personally identifiable "Private Health Information" and to provide a mechanism of authorization for appropriate disclosure. Since April 2003, Institutional Review Boards have assumed the task of interpreting various legislative elements of HIPAA and making recommendations on research protocols. We evaluated the economic impact of HIPAA regulations on the Selenium and Vitamin E Trial, an NCI sponsored chemoprevention trial. Methods: A formative evaluation was conducted of the recruitment process at baseline for a companion study evaluating the effectiveness of a minority recruitment strategy for SELECT. Study accrual data was analyzed in weekly increments beginning January 2003 to December 2003. Patients who consented to the study prior to April 2003 were considered "pre-HIPAA", while patients recruited on or after June 2003 were considered "post-HIPAA"; accounting for a 6 week delay incurred by the IRB review of the revised protocol. Results: A 70.1% decrease in patient accrual (6.7 pts/week vs. 1.9 pts/week, p<.001) occurred following HIPAA enactment. Taking into account a research assistant's salary and time, pre-HIPAA compliance, an accrued patient required 4.1 hours of RA time (personnel cost of $57), while post-HIPAA accrual required 14.1 hours of RA time (personnel cost of $197). Recruitment pre-HIPAA was on target to complete accrual in 60 weeks time (N=400), compared to post-HIPAA accrual, which would require 171 weeks to recruit the remaining 333 patients to the study at the current rate. Conclusions: Although privacy is of the utmost importance in a world of electronic patient information, HIPAA places a considerable burden on research, which questions the ability to conduct cancer studies in a timely and cost-effective manner. No significant financial relationships to disclose.
A Text-Book of Obstetrics.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Microwave radiometric thermometry predicts tissue temperature during ablation Eugene Bak, Wei Zhu, James Regan, Kenneth Carr, Brian VanderBrink, Mark S. Link, Munther K. Homoud, N. A. Mark Estes, III, Paul J. Wang. New England Medical Center, Boston, MA, Microwave Medical Systems, Acton, MA
Journal: Journal of the American College of Cardiology (2001)
Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Authors: Andrew H. Ko, E. Gabriela Chiorean, Eunice Lee Kwak, Heinz-Josef Lenz, Paul I. Nadler, Debra L. Wood, Masamoto Fujimori, Tetsuhi Inada, Hiroyuki Kouji, Robert R. McWilliams
Journal: Journal of Clinical Oncology (2016)

e15721 Background: PRI-724 is a first-in-class small molecule antagonist that inhibits the interaction between β-catenin and its transcriptional coactivator CBP (CREB-binding protein). Preclinical studies of PRI-724 in pancreatic cancer suggest this agent can promote differentiation of chemotherapy-insensitive cancer stem cells and tumor-initiating cells, inhibit stroma formation, and decrease metastatic potential. Methods: Pts with APC, ECOG PS 0-2, measurable disease by RECIST, and progression following 1st-line rx with FOLFIRINOX or FOLFOX were enrolled at 5 centers. A 3+3 dose cohort escalation design was used with standard GEM (1000 mg/m2 on d1, 8, 15 of 28 d cycle) plus escalating doses of PRI-724 administered as a continuous infusion x7 days every other week. DLTs were defined as gr 4 or prolonged gr 3 AEs during cycle 1. Tumor assessments were performed q2 cycles. PK and pharmacodynamic sampling for evaluation of potential biomarkers of PRI-724 activity was performed at multiple time points. Results: A total of 20 pts were enrolled across 3 dose cohorts (PRI-724 at 320, 640 and 905 mg/m2/d). Median age = 60 years (range 51-73). Evaluable pts completed a median of 2 cycles (range, 1 to 7). There were 7 gr 3/4 AEs attributed to study rx (1 abdom pain, 3 neutropenia, 1 anemia, 1 fatigue, and 1 alk phos elevation), none meeting DLT definition. MTD was not reached. Best response by RECIST was stable disease in 8 pts (40%), inc 2 minor responses. 5 of 8 pts (62.5%) with elevated baseline CA19-9 levels showed a marker decline of > 30%. Median PFS = 2.0 months [range, 0.7 to 7.7]. While most pts demonstrated a decline in serum S100P levels at the end of cycle 1 (median decline 49.95%), neither this nor any other serum PD marker evaluated (S100A4, MMP-7, survivin) showed clear correlation with clinical outcomes. Conclusions: To our knowledge, this study is the first to evaluate a unique strategy of modulating Wnt signaling in APC. WhilePRI-724 combined with GEM is safe and demonstrates modest clinical activity, further work is required to identify useful predictive and PD markers for this novel therapeutic approach. Clinical trial information: NCT01764477.
Alms
Authors: Stephen T. Harvey
Journal: Annals of Internal Medicine (2016)

Ad Libitum1 March 2016AlmsStephen T. Harvey, MDStephen T. Harvey, MDFrom Nashville, Tennessee.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-2103 Audio Reading - “Alms” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Alms," by S.T. Harvey. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail No one with youno record to tell us yourhistory medicationswhen you last had something to eatwe have only scars to go bysome of themno doubt madeby your own handwhich the attendinghas raised into the airto demonstratewaxy flexibilityit has stayed there all nightsomeone has lefta pennyin your cupped palm Author, Article, and Disclosure InformationAffiliations: From Nashville, Tennessee.Current Author Address: Stephen T. Harvey, MD; e-mail, [email protected]com PreviousarticleNextarticle Advertisement Audio Reading - “Alms” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Alms," by S.T. Harvey. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 1 March 2016Volume 164, Issue 5Page: 341KeywordsScars ePublished: 1 March 2016 Issue Published: 1 March 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
I. V. Stalinu: Akademiya Nauk USSR sbornik trudov. [Collected Works of Ukrainian Academy of Science (Dedicated to Stalin on His Sixtieth Birthday)]
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Continuing Medical Education: A Man with Fever, Cough, and Rash
Authors: Hélène Bry-Gauillard, Alejandra Cartes, Jacques Young
Journal: New England Journal of Medicine (2014)

ization, after ovarian stimulation in the patient's healthy wife, was proposed, along with recommended genetic counseling.After an initial failure, viable embryos were obtained and transferred, resulting in pregnancy and term delivery of a healthy male baby who is now 16 months of age.The infant was found to be a heterozygous carrier of the paternal CYP21A2 mutation IVS2-13A/C→G.Surgical adrenalectomy has been used to restore fertility in women with 21-hydroxylase deficiency. 5Mitotane can be used as a last resort in men with 21-hydroxylase deficiency and azoospermia in whom there is no response to intensified glucocorticoid treatment, and in whom azoospermia is associated with large testicular adrenal rest tumors, which impede the testicular surgery that might otherwise improve fertility.
Action of Potassium on the Arterioventricular Node in Digitalized Patients
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ueber die Natur und die Herkunft des Trachomerregers und die bei seiner Entstehung zu beobachtende Erscheinung der Mutierung des Gonokokkus Neisser.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gastrin and the Gastroesophageal Sphincter
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Education Programs Sponsored by Government Agencies
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Informatics
Authors: Donald A. B. Lindberg
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Organic anion transport in HepG2 cells: Absence of the high-affinity, chloride-dependent transporter
Authors: A Min
Journal: Hepatology (1991)

In previous studies, we identified a 55 kD organic anion–binding protein in liver cell sinusoidal plasma membrane subfractions. Other investigators identified another 55 kD bromosulfophthalein/bilirubin binding protein on the surface of rat hepatocytes and HepG2 cells and suggested that this protein served as a transporter for these ligands. In this study, transport of 35S-sulfobromophthalein by the human hepatoma cell line, HepG2, was quantified in the presence and absence of bovine serum albumin to further clarify the possible function of these plasma membrane binding proteins. In contrast to results in normal rat hepatocytes, virtually no uptake of 35S-sulfobromophthalein by HepG2 cells in the presence of bovine serum albumin was found. In the absence of albumin, HepG2 cells expressed temperature-dependent uptake of 35S-sulfobromophthalein. However, the high-affinity CI−-dependent sulfobromophthalein transport that characterizes normal rat hepatocytes was absent, as indicated by an approximately 95-fold lower affinity and 170-fold higher capacity of HepG2 cells for sulfobromophthalein compared with previous results with rat hepatocytes. These results suggest that 55 kD sulfobromophthalein/bilirubin–binding protein on the liver cell surface differs from organic anion-binding protein and is not responsible for sulfobromophthalein extraction in the presence of albumin, although it may play some role in lower affinity transport by cells. Immunoblot analysis and metabolic labeling of HepG2 cells demonstrated synthesis of organic anion-binding protein. However, light microscopic immunocytochemistry and immunoprecipitation of surface iodinated rat hepatocytes and HepG2 cells with antibody to a recombinant organic anion-binding protein fusion protein indicated absence of organic anion-binding protein on the surface of HepG2 cells. Because cell surface organic anion-binding protein and the mitochondrial F1-ATPase β-subunit are immunologically highly cross-reactive, the presence of intracellular but not cell surface organic anion-binding protein immunoreactivity in HepG2 cells suggests that the mitochondrial and cell surface forms of this protein are independently regulated. These studies also indicate that demonstration of sulfobromophthalein transport alone cannot be used as evidence for the presence of the high-affinity transporter. (HEPATOLOGY 1991;14:1217–1223.)
GASTRO-INTESTINAL EPIDEMIC AT PEORIA, ILLINOIS
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genomic profiling and efficacy of anti-EGFR therapy in appendiceal adenocarcinoma.
Authors: Maria Ignez Freitas Melro Braghiroli, Garrett Michael Nash, Martin Morris, Jaclyn Frances Hechtman, Efsevia Vakiani, Michael F. Berger, David B. Solit, Leonard Saltz, Andrea Cercek
Journal: Journal of Clinical Oncology (2016)

4102 Background: Metastatic appendiceal adenocarcinoma (AAC) is a heterogenous disease and a large proportion of patients present with diffuse metastases in the peritoneal cavity. Cytotoxic and targeted therapies are typically extrapolated from colorectal adenocarcinoma (CRC), however, the efficacy is not well studied. Herein we investigated the genetic profiles of these tumors in an effort to identify molecular characteristics and potentially actionable mutations, as well as the response to anti-EGFR therapy in RAS/BRAF wild type (wt) AAC. Methods: We identified patients (pts) with ACC treated at MSKCC from 2002 to 2016 who had undergone molecular profiling, either by next generation sequencing using our MSK-IMPACT platform, or by MALDI-TOF mass spectroscopy genotyping (Sequenom). MSK-IMPACT tumors and matched normal samples were analyzed on a 410 gene panel. Sequenom provided an 8 gene panel including KRAS, NRAS, BRAF, and PIK3CA. Via an IRB approved waiver, we collected tumor histology and evaluated those who were RAS/RAF wt and were treated with anti-EGFR therapy. Results: To date, we identified a total 109 AAC patients, of whom 60 had Sequenom testing and 49 had MSK-IMPACT. Among pts analyzed with MSK-IMPACT, 34 had mucinous adenocarcinoma, 6 adenocarcinoma, 9 adenocarcinoma ex goblet cell carcinoid. In total 194 alterations were identified with a median 3.9 alterations/patient (range 0-10). Alterations were seen most commonly in KRAS (57%), GNAS (33%), TP53 (29%), and SMAD4 (6%). Potentially treatable alterations were present in 12% of patients and included BRAF V600E (1), MTOR (2), ERBB2 (1) and NTRK(2). Of the total 109 pts, 51 (47%) were RAS/BRAF wt. Of those, 12 evaluable patients received anti-EGFR therapy with either panitumumab or cetuximab. There were no responders. Conclusions: Mutational sequencing in AAC indicates that 12% have mutations in genes such as BRAF V600E, MTOR, ERBB2 and NTRK with the potential to expand investigational options. Additionally, in RAS/BRAF wt pts, panitumumab/cetuximab does not appear to have therapeutic efficacy comparable to historic controls in RAS/RAF wt CRC.